Results

Gilead Sciences Inc.

06/12/2021 | Press release | Distributed by Public on 06/12/2021 08:31

Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis